title: [Oral administration of beraprost sodium did not exacerbate pulmonary hypertension with CREST syndrome].
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki.
authors.forename: K
authors.initials: K
authors.lastname: Furukawa
authors.forename: S
authors.initials: S
authors.lastname: Ikeda
authors.forename: K
authors.initials: K
authors.lastname: Obase
authors.forename: T
authors.initials: T
authors.lastname: Muroya
authors.forename: H
authors.initials: H
authors.lastname: Oka
authors.forename: M
authors.initials: M
authors.lastname: Kojima
authors.forename: Y
authors.initials: Y
authors.lastname: Miyahara
authors.forename: S
authors.initials: S
authors.lastname: Kohno
mesh_terms: D000368:Aged; D017675:CREST Syndrome / Q000150:complications*; D018450:Disease Progression; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; C048081:beraprost; D011464:Epoprostenol